The Mibro Professional Smartwatch Series will feature two standout models: the GS Explorer and the upcoming GS Explorer S. Both smartwatches are built for those who seek toughness and precision, with military-grade durability that has passed the stringent MIL-STD-810H-2019 tests. Designed to withstand extreme conditions, these models feature dual-frequency GPS for precise tracking, making them ideal for outdoor and adventurous activities. The GS Explorer S will further enhance the user experience with Bluetooth calling functionality, ensuring seamless connectivity while on the move. With water resistance up to 100 meters, these watches are not only rugged but also suitable for swimming and snorkeling.

In addition to its smartwatch lineup, Mibro will launch a new kids’ watch phone, which is designed with safety and connectivity in mind. This child-friendly device comes with features like accurate location tracking and video calling, allowing parents to maintain communication with their children wherever they are. The device is also GDPR-compliant, ensuring that privacy is a top priority. The global launch for this product is scheduled for March and April 2025, except for North America and Latin America.

Mibro will also introduce its Open Wearable Stereo Earphones, a product aimed at those looking for a lightweight, high-quality audio experience. With superior sound quality and a sleek design, these earphones are expected to appeal to a wide range of consumers, from fitness enthusiasts to music lovers. These earphones are slated for a global release in March.

Mibro has steadily established itself as a prominent player in the wearable technology market by consistently introducing innovative products that meet the demands of modern users. The brand’s commitment to quality, functionality, and user-centric design is evident in its new offerings, which cater to a diverse set of needs, from rugged outdoor adventures to child safety and daily convenience.

MWC 2025 will provide a unique opportunity for attendees to explore Mibro’s latest technological advancements, engage with the brand’s team, and discover the future of wearable technology. The company is excited to showcase its innovations and looks forward to forging new collaborations and partnerships at the event.

For more information and to stay updated on product releases, visit Mibro’s official website.

The post Mibro Unveils Cutting-Edge Wearables at MWC 2025 in Barcelona appeared first on EMC UK.

Ovarian cancer, known for being one of the most aggressive and deadly gynecological cancers, is diagnosed in approximately 70% of patients at an advanced stage. While many respond initially to standard chemotherapy, drug resistance often develops, resulting in disease progression and relapse. JIN-001 aims to tackle this critical challenge by targeting heat shock protein 90 (HSP90), a molecular chaperone that enables cancer cells to survive therapeutic stress.

By inhibiting HSP90, JIN-001 hinders cancer cells’ ability to adapt and acquire resistance to chemotherapy, thereby preserving the effectiveness of existing treatment options. The preclinical studies presented at the symposium specifically assessed the drug’s efficacy in combination with established chemotherapeutic agents, providing new hope for patients with drug-resistant cancer.

Researchers evaluated JIN-001’s efficacy in ovarian cancer cell lines, including those resistant to common chemotherapies such as paclitaxel and cisplatin. The study involved treating both normal and resistant ovarian cancer cell lines with varying concentrations of JIN-001, either alone or alongside paclitaxel (PTX) or cisplatin (Cis).

Study Highlights:

• Cell Lines Tested: Researchers utilised ovarian cancer cell lines (OV90, TOV21G, OVCAR3) and their resistant counterparts (OV90/PTX200, TOV21G/PTX100, OVCAR3-CisR) to assess drug efficacy.
• Methods: The study measured cell viability, comparing the outcomes of monotherapy with JIN-001 and combination therapy with standard chemotherapy agents.

The most significant findings arose when JIN-001 was combined with traditional chemotherapy agents. For instance, in the resistant OV90/PTX200 cell line, the combination of JIN-001 and paclitaxel reduced the IC50 value of paclitaxel from 0.204 μM to 0.043 μM, indicating a substantial improvement in therapeutic efficacy. Similarly, in the cisplatin-resistant OVCAR3-CisR cell line, combining JIN-001 with cisplatin lowered its IC50 from 9.643 μM to 0.142 μM.

These interim results suggest that JIN-001 could serve as a breakthrough companion therapy for patients with ovarian cancer. By inhibiting HSP90, the drug enhances the effectiveness of existing chemotherapies and limits cancer’s adaptability, thus reducing the likelihood of treatment resistance.

“The synergy observed between JIN-001 and standard chemotherapy agents is extremely promising. It represents a new treatment paradigm for cancer patients,” said the J INTS BIO research team. “We are dedicated to advancing the clinical development of JIN-001 to validate its efficacy and safety, as we believe it could transform the landscape of cancer treatment.”

Looking ahead, J INTS BIO plans to expedite the clinical development of JIN-001, not only for ovarian cancer but also for other malignancies, including glioblastoma. Collaborative research with MD Anderson Cancer Center on JIN-001’s potential in glioblastoma has yielded positive preclinical results, with a Phase 1 trial expected to commence in 2025.

The post J INTS BIO Unveils Promising Cancer Drug JIN-001 in Barcelona appeared first on EMC UK.